Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm NCT07392060

A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

A Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

Sponsor: Shanghai Jiatan Pharmatech Co., Ltd

Conditions Cervical Cancer Metastatic

Interventions Investigator's Choice of Chemotherapy WX390 1.1mg + Toripalimab 240mg

Updated 1 time since 2026 Last updated: Feb 4, 2026 Started: Feb 28, 2026 Primary completion: Sep 30, 2029 Completion: Jun 30, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cervical Cancer Metastatic and is currently actively recruiting participants. Shanghai Jiatan Pharmatech Co., Ltd leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE3 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Jiatan Pharmatech Co., Ltd

Data source: Shanghai Jiatan Pharmatech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.